期刊
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
卷 31, 期 3, 页码 339-344出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/ijgc-2020-001783
关键词
cervical cancer; endometrial neoplasms; ovarian cancer
资金
- AstraZeneca
With increasing evidence demonstrating acceptable outcomes for fertility-sparing management of early-stage gynecologic cancers, the need for guidance on selecting appropriate candidates for such treatments is growing. It is essential to consider an individual's fertility potential and potential barriers to conception before making major oncologic treatment decisions. A multidisciplinary approach to treatment with early referral to reproductive and maternal-fetal medicine specialists is recommended.
Fertility-sparing management of early-stage gynecologic cancers is becoming more prevalent as increasing evidence demonstrates acceptable oncologic and reproductive outcomes in appropriately selected patients. However, in the absence of randomized controlled trials, most of the commonly used treatment algorithms are based only on observational studies. As women are increasingly postponing childbearing, the need for evidence-based guidance on the optimal selection of appropriate candidates for fertility-sparing therapies is paramount. It is imperative to seriously consider the fertility potential of a given individual prior to making major oncologic treatment decisions that may deviate from the accepted standard of care. It is a disservice to patients to undergo a fertility-sparing procedure in hopes of ultimately achieving a live birth, only to determine later they have poor baseline fertility potential or other substantial barriers to conception including excess financial toxicity. Many women with oncologic diagnoses are of advanced maternal age and their obstetric and neonatal risks must be considered. In the era of advanced assisted reproductive technologies, patients should be provided realistic expectations regarding success rates while understanding the potential oncologic perils. A multidisciplinary approach to the conservative treatment of early-stage gynecologic cancers with early referral to reproductive specialists as well as maternal-fetal medicine specialists is warranted. In this review, we discuss the recommended fertility evaluation for patients with newly diagnosed, early-stage gynecologic cancers who are considering fertility-sparing management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据